Biotech news

Latest breaking stories, features and analysis

Pfizer is acquiring Global Blood Therapeutics
  • Pfizer Inc will get all of GBT’s outstanding shares in a cash agreement of $68.50 per share
  • GBT developed a first-in-class drug, Oxbryta tablets that directly attacks the root cause of this disease.
  • Oxbyrta's net sales came to about roughly $195 million in 2021.
August 9, 2022

Trending news

Market analysis

Is Novavax’s latest wins about to help it shed the meme tag when it reports earnings?
August 5, 2022
Moderna is a buy at $128 as it moves to re-establish support and resistance levels
June 16, 2022
Buy BioNTech SE at the low PE of 2.31
June 16, 2022
Why you should consider buying and accumulating Immatics N.V.
June 3, 2022

More breaking stories